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Preterm infants have a high requirement for preformed dietary DHA, 
approximately 3 times the concentration in mature human milk and infant 
formula, if they are to meet the in utero rapid accumulation of DHA as it 
normally occurs in late pregnancy. 
LCPUFA intervention trials prior to 2000 largely assessed whether infant 
formulas that lacked LCPUFA should be supplemented to the equivalent 
concentrations of DHA and other LCPUFA found in typical human milk of 
women from Westernized societies. 
Trials of LCPUFA supplemented formulas demonstrate that supplementation 
with at least 0.3% total fatty acids as n-3 LCPUFA improved visual 
development, especially in infants born <30 weeks’ gestation or with birth 
weights <1500g. 
Attention is now focused on determining whether there is added advantage to 
meeting the in utero accumulation rate of DHA. 
The largest intervention trial to date indicates that higher dose DHA may 
improve cognitive scores, reduce the risk of developmental delay and reduce 





Infants born preterm are denied the rapid accumulation of docosahexaenoic 
acid (DHA) that occurs during the third trimester in utero. The benefit of long 
chain polyunsaturated fatty acids (LCPUFA) for preterm infants has generated 
much interest over the last 3 decades. Early intervention trials involving 
preterm infants were designed to assess the benefits of supplementing infant 
formulas that lacked DHA with equivalent concentrations of LCPUFA found in 
typical human milk of women from westernized societies. These studies led to 
the inclusion of LCPUFA in all preterm infant formula by the year 2000. Over 
the last decade, attention has moved towards determining the optimal dose of 
DHA required by preterm infants and whether there is advantage in using 
higher doses of DHA (approximately 3 times the concentration in most human 





In examining the effects of long chain polyunsaturated fatty acids (LCPUFAs) on the 
clinical and developmental outcomes of preterm children we have considered it 
logical to separately evaluate the early trials of formula feeding in relatively "healthy” 
low birth weight and very low birth weight infants from the more recent controlled 
trials which assessed higher doses of LCPUFA, particularly considering the role of 
long chain n-3 fatty acids [EPA (eicosapentaenoic acid 20:5 n-3) and DHA 
(docosahexaenoic acid 22:6 n-3)] in more immature, sicker preterm infants. 
 
The early randomized controlled trials of LCPUFA interventions were designed to 
assess whether the infant formula for preterm infants required supplementation with 
n-3 and n-6 LCPUFA as formulas were devoid of all LCPUFA and contained only the 
precursor essential fatty acid (EFA), n-3 alpha-linolenic acid (ALA, 18:3n-3), in small 
amounts and much larger quantities of the n-6 EFA, linoleic acid (LA, 18:2 n-6) 
(Figure 1). 
Such trials were limited to preterm infants who were exclusively fed formula from the 
time enteral feeding began, comparing formulas containing only precursor EFAs with 
those supplemented with LCPUFA. Initial studies focused only on n-3 LCPUFA 
supplementation through fish oils but later studies also included the n-6 LCPUFA, 
arachidonic acid (AA, 20:4n-6) to try and mimic the concentrations of LCPUFA in the 
human milk of women from westernized societies. The infants studied were selected 
from those relatively healthy enough to receive enteral feeds; few of these infants 
had birth weights <1000 g. Almost none of these intervention trials of formula feeding 
intervened with DHA concentrations that exceeded ~ 0.3% of total fatty acids. 
However, the first set of studies used deodorized menhaden oil as a source of DHA, 
this oil contained ~ 0.3-0.4% DHA but also provided ~ 0.6% EPA, thus the total 
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amount of > C 20 n-3 fatty acids was close to 1%. These early studies focused on 
the effects on biochemical endpoints and sensory or cortical neuro-development, 
were of small sample size and thus were not powered to examine relevant clinical 
outcomes. Collectively, these studies led to the gradual inclusion of both n-6 and n-3 
LCPUFAs to premature and later to full term infant formula, so that by the year 2000 
infant formula for preterm infants in developed countries was universally 
supplemented with LCPUFAs equivalent to the concentration found in mature human 
milk of Westernized societies. Attention since then has focused on determining the 
optimal dose of DHA required by preterm infants. 
 
LCPUFA fetal accretion rate and metabolism in preterm infants 
 
 
The measurement of fetal accretion and early ex utero accretion rates represent a 
relatively common approach to estimate a minimum dietary requirement. The 
amount of nutrient required to match accretion at the corresponding post 
conceptional age represents the absolute minimum for the specific nutrient required 
by preterm infants. In addition this amount needs to be corrected by relative 
absorption of the nutrient from human milk or infant formulas and by the oxidative 
losses, since not all that is ingested is absorbed and some of what enters the body is 
used as fuel and cannot be considered available for tissue deposition. Thus, the 
recommendation can be derived by considering the minimum amount that needs to 
be taken to compensate the absorptive losses that will result in a net retention rate 
similar to the intrauterine accretion rate. Most attention has focused on DHA 
accumulation in the central nervous system. Whether the brain is preferentially 
protected when availability of DHA is limited is not known, but the ease with which 
fetal brain DHA is altered by maternal dietary n-3 fatty acid intake suggests that the 
membrane lipid composition of the fetal brain is sensitive to changes in DHA supply 
7  
1
. Because most LCPUFAs accumulate in white adipose tissue and, to a lesser 
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extent, in lean mass and the liver 2, it is important to consider accumulation of DHA 
 
and other LCPUFAs in all relevant organs. 
 
 
Analyses of fetal autopsy tissue yield estimates of intrauterine accretion of LCPUFAs 
during the last trimester. They are: 106 mg/kg/d, 4 mg/kg/d, 212 mg/kg/d and 43 
mg/kg/d for LA, ALA, AA, and DHA, respectively 2. It is likely that the accumulation of 
LCPUFAs is not linear over time during the last trimester. Using these numbers to 
calculate average daily rates of fatty acid accumulation will overestimate or 
underestimate tissue requirements during specific periods of growth. A more precise 
estimate of the fetal accretion rate cannot be determined until more data become 
available. However these recent data based on post-mortem tissue analyses of 
stillbirths suggest that during the third trimester in utero whole body accumulation of 
DHA is of the order of 60mg/kg/day 2. 
 
Based on this information we have estimated that preterm infants, who are born 
early and denied the rapid accumulation of DHA occurring predominantly during the 
last trimester of pregnancy, require DHA in >1% total fatty acids 3. Present research 
 
is now focusing on supplementation strategies to increase the LCPUFA 
concentration in both human milk and infant formula from ~ 0.3% total fatty acids as 
DHA to 1 % in order to match ex utero intakes to in utero accretion during the third 
trimester. Thus in our discussion of the clinical outcomes associated to DHA 
supplementation we will examine the relevant trials in two separate sections, those 
relating to the effects of LCPUFA supplementation of infant formula (comparing no 
LCPUFA vs LCPUFA equivalent to human milk levels) and those trials reporting the 
effects of LCPUFA supplementation that assessed higher doses (comparing 
LCPUFA concentrations equivalent to human milk vs measured in utero accretion 
levels). 
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Effect of LCPUFA supplementation of infant formula on visual development of 
preterm infants 
 
The role of LCPUFA, particularly that of DHA, has been a point of intense 
investigation since the early 1990’s when the first published clinical study showed 
that electroretinographic function and cortical processing of visual stimuli, as 
measured by visual evoked potentials of preterm human infants born weighing 
<1500g, was improved following supplementation of formula with marine oil rich in n- 
 
3 LCPUFA (0.36% of total fatty acids), compared with a control formula high in LA 
 
(n-6 FA present in corn oil) without n-3 LCPUFA and with only trace amounts of ALA 
the metabolic precursor of DHA 4, 5. A third group in the intervention study included 
infants who were fed formula containing soy oil as a source of ALA. The retinal and 
cortical function of the infants in the soy-oil formula group were intermediate between 
the control and marine oil group indicating that preformed n-3 LCPUFA was needed 
for optimal function (matching the performance of human milk fed neonates) (Figure 
2) 4, 5. Importantly the visual function of the n-3 LCPUFA supplemented infants at 36 
weeks post-conceptual age did not differ from a reference group of infants fed human 
milk, which contains LCPUFA or from a group of neonates born at the equivalent 
post- conceptional age studied soon after birth 4. The poignancy of these early 
observations stem from the fact that the control formula used in this clinical study 
derived most of its PUFA from corn oil 4 and had a fatty acid composition not 
dissimilar to the n-3 fatty acid deficient diet used by Neuringer et al 6, 7 who showed 
that infant rhesus monkeys fed n-3 fatty acid deficient formula experienced visual 
loss that was associated with reductions in brain DHA concentration, compared with 





The follow-up assessments of this study also showed similar effect on visual acuity 
 
at 4 months corrected age using electrophysiological assessments 5. The 1990s and 
the early 2000 saw a number of randomised intervention trials of formula 
supplemented with LCPUFA and many of these studies focused their efficacy 
assessment on visual function during infancy. The relevant trials are summarised in 
the most recent Cochrane systematic review and although the review concludes that 
there is no consistent benefit of LCPUFA supplementation of infant formulas for 
preterm infants on visual development, it acknowledges that major differences in 
assessment methods between studies does not allow for a meta-analysis to be 
performed 8. It is therefore interesting to consider the differences between the trials 
that did report some improvement in visual maturity with LCPUFA supplementation, 
compared with the trials reporting no effects. It appears that two factors may be 
influential, first, the dose of n-3 LCPUFA or DHA supplied and second, the maturity 
of the infants included in the trials. Trials of n-3 LCPUFA supplementation are more 
likely to report a beneficial effect on visual development if the majority of infants 
included were < 30 weeks’ gestation or <1500g and the dietary intervention 
contained at least 0.3% total fatty acids as n-3 LCPUFA 4, 9, 10.  Further analysis to 
explain the heterogeneity in responses across different studies has considered not 
only the preformed DHA consumed but the potential contribution to the DHA pool 
from the endogenous conversion of ALA to DHA. Measurements of DHA formation 
from deuterium labelled ALA have revealed low levels of conversion for preterm 
infants (3-5%), this is further compromised by intrauterine growth retardation 11.Thus 
only a small fraction of the ALA fed to a group of growth retarded infants and or low 
birth weight infants is converted to DHA. A meta-regression dose response analysis 
of the effect of DHA supply on visual acuity measures in term infants across multiple 
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studies considering not only the preformed DHA consumed but the total DHA 
 
equivalents formed from ALA desaturation and elongation considering a potential 1, 
 
5 and 10 % conversion revealed a progressively stronger correlation reaching 0.7 
when a 10 % endogenous formation from ALA was considered 12. A similar approach 
with trials involving preterm infants may be useful to better understand the 
differences between individual trials. 
 
 
Effects of LCPUFA supplementation of infant formula on global indices of 
development 
 
Beyond visual function, 7 different randomized trials of formula feeding with LCPUFA 
have assessed global indices of neurodevelopment, generally using the Bayley 
Scales of Infant and Toddler Development (BSITD) 10, 13-18. While some have 
criticized the use of these global indices as being blunt measures of specific 
developmental domains, they nevertheless provide standardized measures that are 
useful to clinicians and families alike. The outcomes of these 7 trials with Bayley 
developmental quotients (DQs) from either the first or second version of the BSITD 
have been summarized in two relatively recent systematic reviews 8, 19. The two 
reviews had somewhat different approaches to combining the data in meta-analyses 
and as a result have differing outcomes. Schulzke et al 8 separately reported DQs of 
preterm children at 12 and 18 months corrected age despite the fact that the BSITD 
is age standardized. They showed no significant difference in cognitive DQ between 
groups at either age (weighted mean difference, WMD, 0.96 points, 95% CI -1.42 to 
3.34 at 12 months corrected age, 4 trials including 364 preterm infants; WMD 2.4 
points, 95% CI -0.33 to 5.12 at 18 months corrected age, 3 trials with 494 preterm 
infants) 8. On the other hand, Smithers et al 19 combined the 12 and 18 month data, 
because all of the DQ scores are age standardized, and conducted a sub-group 
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analysis according to BSITD version as the second version of the BSITD included 
more language and problem solving items for 12 to 18 month old children compared 
with the first version as well as having differences in scoring and administration. 
Smithers et al 19 found that in the meta-analysis of all 7 trials the cognitive DQ of 
LCPUFA treated preterm formula fed children did not differ from control (WMD 2.13 
points, 95% CI -0.87 to 5.14, 976 preterm infants), however, the meta-analysis of 
data from the BSITD version II demonstrated an advantage of LCPUFA treatment 
(WMD, 3.4 points, 95% CI 0.56 to 6.31, 5 trials with 976 infants). These 5 trials 




Beyond 18 months, only one published study has followed children into childhood to 
determine cognitive effects of LCPUFA supplementation in infancy 20. They found no 
difference in intelligence quotient (IQ) but did report that girls who received LCPUFA 
supplemented formula performed significantly better at single word reading accuracy 
and spelling than girls who received unsupplemented formula 20. However, the study 
was limited by large losses to follow-up (55%) making interpretation and 
generalization difficult. It therefore seems that the question of whether LCPUFA 
supplementation of preterm infant formula results in long term neurodevelopmental 
benefit remains open, and may be difficult to definitively answer as formulas for 
preterm infants are now all supplemented with LCPUFA. 
 
LCPUFA needs for LBW and VLBW affected by common diseases of 
prematurity 
 
Considering the potential beneficial effect of dietary LCPUFA on the diseases of 
prematurity demands due consideration of the importance of n-3 and n-6 LCPUFA in 
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modulating the inflammatory immune response as well as the effects of these FA on 
endothelial function, coagulation, inflammation, and neural tissue recovery after 
ischemic/hypoxic injury. These processes define the severity or potential recovery 
from hypoxic/ischemic injury 21. 
Many of the randomized controlled trials comparing the outcomes of preterm infants 
receiving supplemented formulas with either DHA or both DHA and AA with infants 
receiving unsupplemented formula have reported a range of clinical outcomes 
including necrotizing enterocolitis, sepsis, retinopathy or prematurity, intraventricular 
haemorrhage and bronchopulmonary dysplasia (BPD). The relevant trials have been 
summarized in a systematic review and meta-analysis 19. As the clinical signs and 
symptoms used to diagnose these diseases may differ between neonatal units and 
may change with improvements in clinical practice over time, two sensitivity analyses 
were conducted. Apart from combining all data, sensitivity analyses included trials 
only using internationally accepted definitions of the relevant diseases, or trials with 
a low risk of bias based on reporting adequate concealment of randomization and 
analysis according to the intention to treat principle. In meta-analyses of data from 
about 1,500 preterm infants, the risk of necrotizing enterocolitis and sepsis did not 
differ between infants fed LCPUFA supplemented or control formula when all 
available data were included, when necrotizing enterocolitis or sepsis were 
confirmed according to international standards or in the trial quality sensitivity 
analysis 19. There were also no clear differences in retinopathy of prematurity, 
intraventricular haemorrhage, or BPD between preterm infants fed LCPUFA or 
control supplemented formula in overall analyses, or when trials reported diseases 
according to the pre-specified definitions or in the trial quality sensitivity analysis. 
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However, the data were limited by small sample sizes and potential biases 
associated with the studies and the definitions of the diseases 19. 
 
Effects of LCPUFA supplementation designed to mimic in utero accumulation 
 
 
Recent attention has turned to assess whether dietary DHA supplementation to 
match in utero supply results in measurable benefits to the growth, development or 
clinical outcomes of children born preterm with the publication of two relevant 
intervention trials in the last 5 years 22, 23. One trial focused on human milk fed 
preterm infants 22 while the other was inclusive of all infants regardless of whether 
 
they were human milk fed, formula fed or a mixture of both 23. Henriksen et al 
randomly allocated 141 very low birth weight infants (<1500 g) who were human milk 
fed to 6.9% DHA and 6.7% AA (% total fatty acids) and demonstrated an 
improvement in problem solving at 6 months corrected age 22. In a further follow-up 
at 20 months of age, they showed no difference in cognitive DQ but reported a 
 
significant improvement in sustained attention in free play activities 24. No other 
differences in clinical outcomes were reported 22, 24. The relatively small sample size 
and losses to follow-up make interpretation difficult. 
 
The single largest trial, involving over 650 infants born <33 weeks’, was designed to 
assess the delivery of approximately 1% total fatty acids with DHA compared with 
approximately 0.3% DHA supplied either through human milk, infant formula or a 
combination of both in order to mimic typical feeding practices in neonatal units 23. 
All milks contained 0.4-0.5% total fatty acids as AA. The trial was powered for 
neurodevelopmental outcomes and also reported on outcomes related to visual 
development, growth and the typical diseases of prematurity. Although there were no 
significant differences between groups in overall cognitive DQ at 18 months 
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corrected age (MD 1.9; 95% CI −1.0 to 4.7), severe cognitive delay (score <70) was 
reduced from 10.5% in the control group to 5% in the higher DHA group (RR 0.50; 
95% CI 0.26 to 0.93) 23. Furthermore there were significant treatment interactions 
 
indicating that higher DHA treatment had differential responses by infant sex and 
birth weight category. Girls had a significant improvement in cognitive DQ with high- 
DHA treatment, while boys did not differ between groups. For infants born weighing 
<1250 g, the cognitive DQ in the high-DHA group was higher than with standard 
DHA and there were no group difference in infants born weighing at least 1250 g 
(Figure 3). In secondary analyses relating to the clinical outcomes of infants, there 
were no group differences relating to the incidence of sepsis, necrotising 
enterocolitis or intra- ventricular haemorrhage, but high-DHA treatment may in fact 
result in lower rates of BPD particularly in infants born weighing <1250g and male 
infants 23, 25. Other secondary analyses indicated that the high-DHA group had better 
visual acuity at 4 months of age compared with the standard-DHA group 26 and that 
infants fed higher DHA were 0·7 cm (95% CI 0·1, 1·4 cm; P=0·02) longer at 18 
months corrected age 27. There was an interaction effect between treatment and 
birth weight strata for weight and length. Higher DHA resulted in increased length in 
infants born weighing ≥1250 g, at 4 months corrected age and in both weight and 
length at 12 and 18 months corrected age 27. While complex, these data indicate that 
DHA up to 1% total dietary fatty acids is safe, does not adversely affect growth and 
may in fact have other clinical advantages in relation to BPD and early childhood 
neurodevelopmental outcomes for important subgroups of infants. The relatively 
consistent benefit of higher dietary DHA, designed to emulate in utero accretion, in 
the smallest and most immature infants is consistent with the hypothesis that 
suboptimal DHA availability during the critical neonatal period results in disturbed 
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DHA accumulation and has consequences on development. Current large-scale 
trials, such as N3RO (N-3 LCPUFA for Respiratory Outcomes in infants born <29 
weeks’), should provide conclusive and contemporary data for higher-dose DHA 
supplementation to the most vulnerable infants as well as offer some new insights 
into the mechanisms by which higher-dose dietary DHA may work to dampen 
inflammatory immune responses.  
Future directions of relevance to neonatal and perinatal medicine 
Over the past three decades knowledge on DHA effects on gene expression and on 
the production of n-3 derived eicosanoids has expanded significantly beyond the 
areas we have covered in this short review. Animal studies using a genetic 
modification have produced a rat that over expresses delta-6 desaturase (fat-1 rat), 
allowing significant experimentation in animals that have increased DHA content of 
all tissues, as well as the unique models of stroke as a hypoxic injury that can be 
treated with DHA-derived compounds capable of resolving the associated 
inflammatory insult. Due to their potential relevance to neonatal health and/or 
amelioration of neonatal conditions affecting very low birth weight infants we suggest 
some areas where further research may reveal significant benefits: 
(1) Preventing excessive inflammation, especially in the gut and lung and 
understanding some of the mechanisms by which dietary n-3 LCPUFA may 
alter the onset and progression of NEC and BPD 
(2) Protecting from hypoxic/ischemic organ damage as demonstrated by the use 
of DHA derivatives in ischemic brain infarctions and may have relevance to 
the hypoxic/ischemic brain injury experienced with IVH. 
(3) Some of the latest trials suggesting that higher dose DHA administered in 
pregnancy reduces the risk of early preterm birth may offer additional 
treatment modalities with potential to administer DHA to mothers who 
16  
potentially will deliver preterm or growth retarded infants in order to prevent or 






The essentiality of LCPUFA, particularly DHA, for preterm infants has been a point of 
discussion in the literature for some 25 years. While most of the biochemical studies 
clearly show the insufficiency of DHA in the diet of preterm infants, the picture has 
not been so clear from the intervention trials with clinical and developmental 
outcomes. The early intervention trials, and in fact the majority of the controlled trials, 
were designed to assess whether infant formulas that were devoid of LCPUFA 
should be supplemented to the equivalent concentrations of DHA and other LCPUFA 
found in typical human milk. Intervention studies involving exclusively formula fed 
preterm infants have demonstrated improved visual development using 
neurosensory and behavioral techniques and the trials showing the most consistent 
benefit included those in which the majority of infants were born <30 weeks’ 
gestation or had birth weights <1500g and the dietary intervention contained at least 
0.3% total fatty acids as n-3 LCPUFA. With the universal supplementation of all 
preterm infant formula with LCPUFA since the year 2000, attention has since 
focused on determining the specific dietary requirement of DHA and whether there is 
added advantage to meeting the in utero accumulation rate of DHA which is 
approximately 3 times the concentration in most human milks and infant formula. 
The largest intervention trial addressing this question to date indicates that higher 
dose DHA may improve cognitive scores, reduce the risk of developmental delay 
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